background and overview[1]
3-amino-3-(2-nitrophenyl)propionic acid can be used as a pharmaceutical synthesis intermediate. if 3-amino-3-(2-nitrophenyl)propionic acid is inhaled, move the patient to fresh air; if skin contact occurs, remove contaminated clothing and rinse skin thoroughly with soap and water, if any if you feel discomfort, seek medical attention; if contact with eyes occurs, separate eyelids, rinse with running water or saline, and seek medical attention immediately; if ingested, rinse mouth immediately, do not induce vomiting, and seek medical attention immediately.
preparation [1]
the preparation of 3-amino-3-(2-nitrophenyl)propionic acid is as follows:
the specific steps are as follows: stir o-nitrobenzaldehyde (20.4 g, 0.135 mol), formic acid (20.3 ml, 0.539 mol) and malonic acid (18.3 g, 0.176 mol) at 45 °c for half an hour, and then ammonium formate (21.3 g, 0.338 mol) was added to it, the reaction temperature was raised to 70°c and stirred for one hour, then stirred at 95°c for four hours, then concentrated hydrochloric acid (50 ml) was added and the temperature was maintained for one hour. , cool, add 25ml water, wash twice with ethyl acetate (2x25ml), adjust the ph of the water phase to 4.2 with 50% potassium hydroxide solution, filter the precipitated solid, and dry it under vacuum to obtain 18.33 g of yellow solid, yield 64.6%.
apply[1]
3-amino-3-(2-nitrophenyl)propionic acid can be used as a pharmaceutical synthesis intermediate. if the following reaction occurs:
the specific steps are: dissolve 3-amino-3-(2-nitrophenyl)propionic acid (15 g, 71.4mmol) in 5% sodium hydroxide solution (85 ml) and 85% hydrazine hydrate (5ml) in the mixed solution, the reaction was heated to 80 ° c, and then raney nickel (2 × 25 mg) was carefully added. after the reaction for half an hour, it was cooled, and the ph was adjusted to 2 with 6w hydrochloric acid. the precipitated solid was filtered and vacuum dried to obtain yellow solid 6.86 g, yield 54.5%.
main reference materials
[1] wo2013071880 nitrogen-containing dicyclic compounds as crth2 antagonists